抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）

许婷婷; 胡超苏; 李宝生

doi:10.19401/j.cnki.1007-3639.2023.01.010

您当前的位置：

首页 >

文章列表页 >

抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）

指南与共识 | 更新时间：2025-12-31

- 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）
- Clinical consensus on the treatment of locally advanced squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2023 edition)
- 中国癌症杂志 2023年33卷第1期页码：81-94
- 作者机构：
  
  1. 中国临床肿瘤学会头颈肿瘤专家委员会
  2. 中国医师协会肿瘤放射治疗医师分会
- 作者简介：
  
  [ "许婷婷（ORCID: 0000-0002-5920-808X），博士，副主任医师。" ]
  胡超苏（ORCID: 0000-0001-6407-3311），博士，主任医师；
  李宝生（ORCID:0000-0001-9952-8312），博士，主任医师，山东第一医科大学附属肿瘤医院副院长，山东第一医科大学临床与基础医学院副院长/肿瘤学系主任。
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.01.010
  中图分类号： R739.91
- 收稿：2022-10-21，
  
  修回：2023-01-03，
  
  纸质出版：2023-01-30
- 稿件说明：
移动端阅览
许婷婷, 胡超苏, 李宝生. 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）[J]. 中国癌症杂志, 2023,33(1):81-94.

Tingting XU, Chaosu HU, Baosheng LI. Clinical consensus on the treatment of locally advanced squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2023 edition)[J]. China Oncology, 2023, 33(1): 81-94.
许婷婷, 胡超苏, 李宝生. 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）[J]. 中国癌症杂志, 2023,33(1):81-94. DOI： 10.19401/j.cnki.1007-3639.2023.01.010.

Tingting XU, Chaosu HU, Baosheng LI. Clinical consensus on the treatment of locally advanced squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2023 edition)[J]. China Oncology, 2023, 33(1): 81-94. DOI： 10.19401/j.cnki.1007-3639.2023.01.010.

摘要

头颈部鳞状细胞癌（squamous cell carcinoma of the head and neck，SCCHN）是最常见的一类头颈部肿瘤。由于早期症状不典型，大多数SCCHN患者确诊时已处于局部晚期。以标准剂量顺铂为基础的同期放化疗（chemoradiotherapy，CRT）是局部晚期SCCHN患者的标准非手术治疗模式。但同期CRT的近期和远期毒性问题不容忽视，对于无法耐受标准治疗强度的患者，在治疗策略的选择上要兼顾疗效、器官毒性和器官功能。几乎所有的SCCHN都会存在表皮生长因子受体（epidermal growth factor receptor，EGFR）过表达。抗EGFR单抗通过与EGFR结合，竞争性阻断内源性EGFR天然配体，阻碍EGFR二聚体的形成，抑制肿瘤细胞生长；此外，抗EGFR单抗可通过影响细胞周期、DNA损伤修复及血管生成等多种途径发挥放疗增敏作用。既往Ⅲ期临床研究表明，对比单纯放疗，放疗联合西妥昔单抗可显著改善局部晚期SCCHN患者的局部区域控制，延长总生存期。临床工作中合理地应用抗EGFR单抗仍面临诸多挑战，包括适用人群的判定标准、应用时机、联合方案的选择及不良事件管理等都需要进一步明确和规范。本共识专家组以循证医学证据为基础、相关指南为依据，经充分讨论形成《抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）》。根据本共识的专家建议，局部晚期SCCHN患者在同期CRT前，应评估患者对标准剂量顺铂治疗的耐受性和治疗毒性。对于无法耐受标准剂量顺铂治疗的患者，或在接受多西他赛+顺铂+5-氟尿嘧啶（TPF）方案诱导化疗后出现顺铂相关毒性的患者，可选择放疗联合西妥昔单抗方案。对于有降期或器官功能保留需求、拟行诱导治疗的患者，标准诱导治疗方案为TPF方案，不能耐受TPF方案毒性的患者，可用西妥昔单抗替代5-氟尿嘧啶，采用TPE方案。安全性方面，放疗联合西妥昔单抗相关常见不良反应包括痤疮样皮疹、口腔黏膜炎、放射性皮炎等，可以通过治疗前预防、治疗过程中早期识别和及时干预进行全面、分级管理。

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) is the most common head and neck tumor. Patients are generally diagnosed with advanced stage attributed to no clinically evident symptom at the early stage. For locally advanced SCCHN

cisplatin-based concurrent chemoradiotherapy (CRT) is the standard non-surgical treatment. However

the tolerance to high-dose cisplatin is poor owing to the high prevalence of comorbidities in patients with SCCHN. There are also concerns on the acute and late toxicities of CRT. Epidermal growth factor receptor (EGFR) is proved to be overexpressed in most SCCHN and it is associated with resistance to cytotoxic agents and radiotherapy leading to poor prognosis. Anti-EGFR antibody

which competes with EGFR ligands

can lead to receptor internalization

antibody-receptor complex down-regulation and tumor death. In addition

anti-EGFR antibody can play a role in radiosensitization by affecting cell cycle

DNA damage repair and angiogenesis. Radiotherapy combined with anti-EGFR antibody was demonstrated to improve survival when compared to radiotherapy alone

while consensus on anti-EGFR antibody delivery in the eligible patients

optimal intervention time and the management of adverse effects when combined with radiotherapy are yet warranted. According to the current recommendations

all patients with locally advanced SCCHN should be assessed for the tolerance of standard dose cisplatin prior to CRT. Radiotherapy with cetuximab is an alternative for patients who cannot tolerate. For those who received induction chemotherapy with the purpose of tumor downstaging or organ preservation

the standard regimen is TPF (docetaxel+cisplatin+5-fluorouracil) scheme. TPE scheme

using cetuximab as a substitution for fluorouracil

is an option for toxicities reducing. Managements of skin reactions

oral mucositis and radiation dermatitis are proposed.

关键词

Keywords

references

MACHIELS J P , RENÉ LEEMANS C , GOLUSINSKI W , et al . Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2020 , 31 ( 11 ): 1462 - 1475 . DOI: 10.1016/j.annonc.2020.07.011 http://doi.org/10.1016/j.annonc.2020.07.011

ARGIRIS A , KARAMOUZIS M V , RABEN D , et al . Head and neck cancer [J ] . Lancet , 2008 , 371 ( 9625 ): 1695 - 1709 . DOI: 10.1016/S0140-6736(08)60728-X http://doi.org/10.1016/S0140-6736(08)60728-X

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.21660 http://doi.org/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660

ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南(2022年版) [M ] . 北京 : 人民卫生出版社 , 2022 .

Working Committee of the Guidelines of the Chinese Society of Clinical Oncology . Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Head and Neck Tumors (2022 Edition) [M ] . Beijing : People’s Medical Publishing House , 2022 .

LACAS B , CARMEL A , LANDAIS C , et al . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19 805 patients, on behalf of MACH-NC group [J ] . Radiother Oncol , 2021 , 156 : 281 - 293 . DOI: 10.1016/j.radonc.2021.01.013 http://doi.org/10.1016/j.radonc.2021.01.013 https://linkinghub.elsevier.com/retrieve/pii/S016781402100013X https://linkinghub.elsevier.com/retrieve/pii/S016781402100013X

CHUNG C H , ELY K , MCGAVRAN L , et al . Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas [J ] . J Clin Oncol , 2006 , 24 ( 25 ): 4170 - 4176 . DOI: 10.1200/JCO.2006.07.2587 http://doi.org/10.1200/JCO.2006.07.2587

AKIMOTO T , HUNTER N R , BUCHMILLER L , et al . Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas [J ] . Clin Cancer Res , 1999 , 5 ( 10 ): 2884 - 2890 .

MILAS L , MASON K , HUNTER N , et al . In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody [J ] . Clin Cancer Res , 2000 , 6 ( 2 ): 701 - 708 .

CHEN D J , NIRODI C S . The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage [J ] . Clin Cancer Res , 2007 , 13 ( 22 Pt 1 ): 6555 - 6560 . DOI: 10.1158/1078-0432.CCR-07-1610 http://doi.org/10.1158/1078-0432.CCR-07-1610

KURAI J , CHIKUMI H , HASHIMOTO K , et al . Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines [J ] . Clin Cancer Res , 2007 , 13 ( 5 ): 1552 - 1561 . DOI: 10.1158/1078-0432.CCR-06-1726 http://doi.org/10.1158/1078-0432.CCR-06-1726

TRIVEDI S , SRIVASTAVA R M , CONCHA-BENAVENTE F , et al . Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients [J ] . Clin Cancer Res , 2016 , 22 ( 21 ): 5229 - 5237 .

HUANG S M , BOCK J M , HARARI P M . Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck [J ] . Cancer Res , 1999 , 59 ( 8 ): 1935 - 1940 .

HERBST R S , HONG W K . IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer [J ] . Semin Oncol , 2002 , 29 ( 5 Suppl 14 ): 18 - 30 .

HERBST R S , LANGER C J . Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers [J ] . Semin Oncol , 2002 , 29 ( 1 Suppl 4 ): 27 - 36 . DOI: 10.1053/sonc.2002.31525 http://doi.org/10.1053/sonc.2002.31525

KIMURA H , SAKAI K , ARAO T , et al . Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor [J ] . Cancer Sci , 2007 , 98 ( 8 ): 1275 - 1280 . DOI: 10.1111/j.1349-7006.2007.00510.x http://doi.org/10.1111/j.1349-7006.2007.00510.x https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2007.00510.x https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2007.00510.x

SRIVASTAVA R M , LEE S C , ANDRADE FILHO P A , et al . Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients [J ] . Clin Cancer Res , 2013 , 19 ( 7 ): 1858 - 1872 . DOI: 10.1158/1078-0432.CCR-12-2426 http://doi.org/10.1158/1078-0432.CCR-12-2426

BONNER J A , HARARI P M , GIRALT J , et al . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J ] . N Engl J Med , 2006 , 354 ( 6 ): 567 - 578 . DOI: 10.1056/NEJMoa053422 http://doi.org/10.1056/NEJMoa053422 http://www.nejm.org/doi/abs/10.1056/NEJMoa053422 http://www.nejm.org/doi/abs/10.1056/NEJMoa053422

BONNER J A , HARARI P M , GIRALT J , et al . Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J ] . Lancet Oncol , 2010 , 11 ( 1 ): 21 - 28 . DOI: 10.1016/S1470-2045(09)70311-0 http://doi.org/10.1016/S1470-2045(09)70311-0

国家药品监督管理局 . 2022年06月20日药品批准证明文件待领取信息发布 [EB/OL ] . [ 2022-12-20 ] . https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220620141308104.html https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220620141308104.html https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220620141308104.html.

National Medical Products Administration . On June 20, 2022, the drug approval certificate was issued [EB/OL ] . [ 2022-12-20 ] . https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220620141308104.html https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220620141308104.html https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220620141308104.html.

MATEO C , MORENO E , AMOUR K , et al . Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity [J ] . Immunotechnology , 1997 , 3 ( 1 ): 71 - 81 .

国家卫生健康委员会合理用药专家委员会 . 新型抗肿瘤药物临床应用指导原则(2021年版) [EB/OL ] . [ 2022-12-20 ] . http://www.nhc.gov.cn/yzygj/s7659/202112/0fbf3f04092b4d67be3b3e89040d8489.shtml http://www.nhc.gov.cn/yzygj/s7659/202112/0fbf3f04092b4d67be3b3e89040d8489.shtml http://www.nhc.gov.cn/yzygj/s7659/202112/0fbf3f04092b4d67be3b3e89040d8489.shtml.

Expert Committee on Rational Drug Use of the National Health Commission . Guiding principles for clinical application of new antitumor drugs (2021 edition) [EB/OL ] . [ 2022-12-20 ] . http://www.nhc.gov.cn/yzygj/s7659/202112/0fbf3f04092b4d67be3b3e89040d8489.shtml http://www.nhc.gov.cn/yzygj/s7659/202112/0fbf3f04092b4d67be3b3e89040d8489.shtml http://www.nhc.gov.cn/yzygj/s7659/202112/0fbf3f04092b4d67be3b3e89040d8489.shtml.

SCHNEIDER-MERCK T , LAMMERTS VAN BUEREN J J , BERGER S , et al . Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage [J ] . J Immunol , 2010 , 184 ( 1 ): 512 - 520 .

NGUYEN-TAN P F , ZHANG Q , ANG K K , et al . Randomized phase Ⅲ trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long-term report of efficacy and toxicity [J ] . J Clin Oncol , 2014 , 32 ( 34 ): 3858 - 3866 . DOI: 10.1200/JCO.2014.55.3925 http://doi.org/10.1200/JCO.2014.55.3925 https://ascopubs.org/doi/10.1200/JCO.2014.55.3925 https://ascopubs.org/doi/10.1200/JCO.2014.55.3925

LE X N , HANNA E Y . Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined [J ] . Ann Transl Med , 2018 , 6 ( 11 ): 229 . DOI: 10.21037/atm.2018.05.10 http://doi.org/10.21037/atm.2018.05.10

LOONG H H , MA B B , LEUNG S F , et al . Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma [J ] . Radiother Oncol , 2012 , 104 ( 3 ): 300 - 304 . DOI: 10.1016/j.radonc.2011.12.022 http://doi.org/10.1016/j.radonc.2011.12.022

NAKANO K , SATO Y , TOSHIYASU T , et al . Predictive factors of head and neck squamous cell carcinoma patient tolerance to high-dose cisplatin in concurrent chemoradiotherapy [J ] . Mol Clin Oncol , 2016 , 4 ( 2 ): 303 - 309 .

NUYTS S , DIRIX P , CLEMENT P M , et al . Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma [J ] . Int J Radiat Oncol Biol Phys , 2009 , 73 ( 4 ): 1088 - 1095 . DOI: 10.1016/j.ijrobp.2008.05.042 http://doi.org/10.1016/j.ijrobp.2008.05.042 https://linkinghub.elsevier.com/retrieve/pii/S0360301608009541 https://linkinghub.elsevier.com/retrieve/pii/S0360301608009541

MACHTAY M , MOUGHAN J , TROTTI A , et al . Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis [J ] . J Clin Oncol , 2008 , 26 ( 21 ): 3582 - 3589 . DOI: 10.1200/JCO.2007.14.8841 http://doi.org/10.1200/JCO.2007.14.8841

NORONHA V , JOSHI A , PATIL V M , et al . Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase Ⅲ randomized noninferiority trial [J ] . J Clin Oncol , 2018 , 36 ( 11 ): 1064 - 1072 . DOI: 10.1200/JCO.2017.74.9457 http://doi.org/10.1200/JCO.2017.74.9457 https://ascopubs.org/doi/10.1200/JCO.2017.74.9457 https://ascopubs.org/doi/10.1200/JCO.2017.74.9457

Sharma A , Kumar M , Bhasker S , et al . An open-label, noninferiority phase Ⅲ RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial) [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 6004 - 6004 .

AHN M J , D'CRUZ A , VERMORKEN J B , et al . Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review [J ] . Oral Oncol , 2016 , 53 : 10 - 16 . DOI: 10.1016/j.oraloncology.2015.11.019 http://doi.org/10.1016/j.oraloncology.2015.11.019 https://linkinghub.elsevier.com/retrieve/pii/S1368837515003978 https://linkinghub.elsevier.com/retrieve/pii/S1368837515003978

MCCUSKER M G , MEHRA R , AMR S , et al . Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment [J ] . Head Neck , 2022 , 44 ( 3 ): 749 - 759 . DOI: 10.1002/hed.26965 http://doi.org/10.1002/hed.26965 https://onlinelibrary.wiley.com/doi/10.1002/hed.26965 https://onlinelibrary.wiley.com/doi/10.1002/hed.26965

HAMAUCHI S , YOKOTA T , MIZUMACHI T , et al . Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin [J ] . Int J Clin Oncol , 2019 , 24 ( 5 ): 468 - 475 . DOI: 10.1007/s10147-018-01392-9 http://doi.org/10.1007/s10147-018-01392-9

GIRALT J , TRIGO J , NUYTS S , et al . Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial [J ] . Lancet Oncol , 2015 , 16 ( 2 ): 221 - 232 . DOI: 10.1016/S1470-2045(14)71200-8 http://doi.org/10.1016/S1470-2045(14)71200-8

ANG K K , HARRIS J , WHEELER R , et al . Human papillomavirus and survival of patients with oropharyngeal cancer [J ] . N Engl J Med , 2010 , 363 ( 1 ): 24 - 35 . DOI: 10.1056/NEJMoa0912217 http://doi.org/10.1056/NEJMoa0912217 http://www.nejm.org/doi/abs/10.1056/NEJMoa0912217 http://www.nejm.org/doi/abs/10.1056/NEJMoa0912217

GILLISON M L , TROTTI A M , HARRIS J , et al . Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial [J ] . Lancet , 2019 , 393 ( 10166 ): 40 - 50 . DOI: S0140-6736(18)32779-X http://doi.org/S0140-6736(18)32779-X

MEHANNA H , ROBINSON M , HARTLEY A , et al . Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial [J ] . Lancet , 2019 , 393 ( 10166 ): 51 - 60 . DOI: S0140-6736(18)32752-1 http://doi.org/S0140-6736(18)32752-1

RISCHIN D , KING M , KENNY L , et al . Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01)-a Trans-Tasman radiation oncology group study [J ] . Int J Radiat Oncol Biol Phys , 2021 , 111 ( 4 ): 876 - 886 . DOI: 10.1016/j.ijrobp.2021.04.015 http://doi.org/10.1016/j.ijrobp.2021.04.015 https://linkinghub.elsevier.com/retrieve/pii/S036030162100376X https://linkinghub.elsevier.com/retrieve/pii/S036030162100376X

RISCHIN D , MEHANNA H , YOUNG R J , et al . Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103 + immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials [J ] . Ann Oncol , 2022 , 33 ( 8 ): 804 - 813 . DOI: 10.1016/j.annonc.2022.04.074 http://doi.org/10.1016/j.annonc.2022.04.074 https://linkinghub.elsevier.com/retrieve/pii/S0923753422007645 https://linkinghub.elsevier.com/retrieve/pii/S0923753422007645

ANG K K , ZHANG Q , ROSENTHAL D I , et al . Randomized phase Ⅲ trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage Ⅲ to Ⅳ head and neck carcinoma: RTOG 0522 [J ] . J Clin Oncol , 2014 , 32 ( 27 ): 2940 - 2950 . DOI: 10.1200/JCO.2013.53.5633 http://doi.org/10.1200/JCO.2013.53.5633 https://ascopubs.org/doi/10.1200/JCO.2013.53.5633 https://ascopubs.org/doi/10.1200/JCO.2013.53.5633

WEIDHAAS J B , HARRIS J , SCHAUE D , et al . The KRAS -variant and cetuximab response in head and neck squ amous cell cancer: a secondary analysis of a randomized clinical trial [J ] . JAMA Oncol , 2017 , 3 ( 4 ): 483 - 491 . DOI: 10.1001/jamaoncol.2016.5478 http://doi.org/10.1001/jamaoncol.2016.5478 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.5478 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.5478

顾湘 , 刘坤 , 苟浩成 , 等 . T 4b 期下咽癌非手术综合治疗77例回顾性分析 [J ] . 中华耳鼻咽喉头颈外科杂志 , 2022 , 57 ( 1 ): 22 - 28 .

GU X , LIU K , GOU H C , et al . Retrospective analysis on 77 cases of T 4b hypopharyngeal carcinoma treated by non-surgical treatments [J ] . Chin J Otorhinolaryngol Head Neck Surg , 2022 , 57 ( 1 ): 22 - 28 .

PATIL V M , NORONHA V , JOSHI A , et al . A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer [J ] . Cancer , 2019 , 125 ( 18 ): 3184 - 3197 . DOI: 10.1002/cncr.32179 http://doi.org/10.1002/cncr.32179

MESÍA R , HENKE M , FORTIN A , et al . Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial [J ] . Lancet Oncol , 2015 , 16 ( 2 ): 208 - 220 . DOI: 10.1016/S1470-2045(14)71198-2 http://doi.org/10.1016/S1470-2045(14)71198-2

GHI M G , PACCAGNELLA A , FERRARI D , et al . Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase Ⅱ-Ⅲ trial [J ] . Ann Oncol , 2017 , 28 ( 9 ): 2206 - 2212 . DOI: 10.1093/annonc/mdx299 http://doi.org/10.1093/annonc/mdx299 https://linkinghub.elsevier.com/retrieve/pii/S0923753419352512 https://linkinghub.elsevier.com/retrieve/pii/S0923753419352512

LEFEBVRE J L , POINTREAU Y , ROLLAND F , et al . Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase Ⅱ study [J ] . J Clin Oncol , 2013 , 31 ( 7 ): 853 - 859 .

JANORAY G , POINTREAU Y , ALFONSI M , et al . Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: long-term results of the TREMPLIN randomised GORTEC trial [J ] . Eur J Cancer , 2020 , 133 : 86 - 93 . DOI: S0959-8049(20)30207-0 http://doi.org/S0959-8049(20)30207-0

VERMORKEN J B , REMENAR E , VAN HERPEN C , et al . Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer [J ] . N Engl J Med , 2007 , 357 ( 17 ): 1695 - 1704 . DOI: 10.1056/NEJMoa071028 http://doi.org/10.1056/NEJMoa071028 http://www.nejm.org/doi/abs/10.1056/NEJMoa071028 http://www.nejm.org/doi/abs/10.1056/NEJMoa071028

POSNER M R , HERSHOCK D M , BLAJMAN C R , et al . Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer [J ] . N Engl J Med , 2007 , 357 ( 17 ): 1705 - 1715 . DOI: 10.1056/NEJMoa070956 http://doi.org/10.1056/NEJMoa070956 http://www.nejm.org/doi/abs/10.1056/NEJMoa070956 http://www.nejm.org/doi/abs/10.1056/NEJMoa070956

HADDAD R , O'NEILL A , RABINOWITS G , et al . Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial [J ] . Lancet Oncol , 2013 , 14 ( 3 ): 257 - 264 . DOI: 10.1016/S1470-2045(13)70011-1 http://doi.org/10.1016/S1470-2045(13)70011-1

COHEN E E , KARRISON T G , KOCHERGINSKY M , et al . Phase Ⅲ randomized trial of induction chemotherapy in patients with N 2 or N 3 locally advanced head and neck cancer [J ] . J Clin Oncol , 2014 , 32 ( 25 ): 2735 - 2743 . DOI: 10.1200/JCO.2013.54.6309 http://doi.org/10.1200/JCO.2013.54.6309 https://ascopubs.org/doi/10.1200/JCO.2013.54.6309 https://ascopubs.org/doi/10.1200/JCO.2013.54.6309

GEOFFROIS L , MARTIN L , DE RAUCOURT D , et al . Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase Ⅲ randomized trial [J ] . J Clin Oncol , 2018 , 36 ( 31 ): 3077 - 3083 . DOI: 10.1200/JCO.2017.76.2591 http://doi.org/10.1200/JCO.2017.76.2591 https://ascopubs.org/doi/10.1200/JCO.2017.76.2591 https://ascopubs.org/doi/10.1200/JCO.2017.76.2591

Department of Veterans Affairs Laryngeal Cancer Study Group , WOLF G T , FISHER S G , et al . Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer [J ] . N Engl J Med , 1991 , 324 ( 24 ): 1685 - 1690 . DOI: 10.1056/NEJM199106133242402 http://doi.org/10.1056/NEJM199106133242402 http://www.nejm.org/doi/abs/10.1056/NEJM199106133242402 http://www.nejm.org/doi/abs/10.1056/NEJM199106133242402

LEFEBVRE J L , CHEVALIER D , LUBOINSKI B , et al . Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase Ⅲ trial. EORTC Head and Neck Cancer Cooperative Group [J ] . J Natl Cancer Inst , 1996 , 88 ( 13 ): 890 - 899 . DOI: 10.1093/jnci/88.13.890 http://doi.org/10.1093/jnci/88.13.890 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/88.13.890 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/88.13.890

FORASTIERE A A , GOEPFERT H , MAOR M , et al . Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer [J ] . N Engl J Med , 2003 , 349 ( 22 ): 2091 - 2098 . DOI: 10.1056/NEJMoa031317 http://doi.org/10.1056/NEJMoa031317 http://www.nejm.org/doi/abs/10.1056/NEJMoa031317 http://www.nejm.org/doi/abs/10.1056/NEJMoa031317

FORASTIERE A A , ZHANG Q , WEBER R S , et al . Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer [J ] . J Clin Oncol , 2013 , 31 ( 7 ): 845 - 852 . DOI: 10.1200/JCO.2012.43.6097 http://doi.org/10.1200/JCO.2012.43.6097

ARGIRIS A , HERON D E , SMITH R P , et al . Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer [J ] . J Clin Oncol , 2010 , 28 ( 36 ): 5294 - 5300 . DOI: 10.1200/JCO.2010.30.6423 http://doi.org/10.1200/JCO.2010.30.6423

DIETZ A , WICHMANN G , KUHNT T , et al . Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-Ⅱ [J ] . Ann Oncol , 2018 , 29 ( 10 ): 2105 - 2114 . DOI: 10.1093/annonc/mdy332 http://doi.org/10.1093/annonc/mdy332 https://linkinghub.elsevier.com/retrieve/pii/S092375341934205X https://linkinghub.elsevier.com/retrieve/pii/S092375341934205X

KEIL F , HARTL M , ALTORJAI G , et al . Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: results of a randomised phase Ⅱ AGMT trial [J ] . Eur J Cancer , 2021 , 151 : 201 - 210 . DOI: 10.1016/j.ejca.2021.03.051 http://doi.org/10.1016/j.ejca.2021.03.051 https://linkinghub.elsevier.com/retrieve/pii/S0959804921002185 https://linkinghub.elsevier.com/retrieve/pii/S0959804921002185

LACOUTURE M E . Mechanisms of cutaneous toxicities to EGFR inhibitors [J ] . Nat Rev Cancer , 2006 , 6 ( 10 ): 803 - 812 . DOI: 10.1038/nrc1970 http://doi.org/10.1038/nrc1970

PINTO C , BARONE C A , GIROLOMONI G , et al . Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: update of the Italian expert recommendations [J ] . Am J Clin Oncol , 2016 , 39 ( 4 ): 407 - 415 . DOI: 10.1097/COC.0000000000000291 http://doi.org/10.1097/COC.0000000000000291 https://journals.lww.com/00000421-201608000-00015 https://journals.lww.com/00000421-201608000-00015

郭晔 , 张陈平 . 抗EGFR单抗治疗复发/转移性头颈部鳞状细胞癌临床共识(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 12 ): 1220 - 1232 .

GUO Y , ZHANG C P . Expert consensus on the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody(2021 edition) [J ] . China Oncol , 2021 , 31 ( 12 ): 1220 - 1232 .

王刚 , 项蕾红 , 袁瑛 , 等 . 抗EGFR单抗治疗相关皮肤不良反应临床处理专家共识 [J ] . 实用肿瘤杂志 , 2021 , 36 ( 3 ): 195 - 201 .

WANG G , XIANG L H , YUAN Y , et al . Expert consensus on management of skin toxicities induced by anti-EGFR monoclonal antibody [J ] . J Pract Oncol , 2021 , 36 ( 3 ): 195 - 201 .

VERA-LLONCH M , OSTER G , HAGIWARA M , et al . Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma [J ] . Cancer , 2006 , 106 ( 2 ): 329 - 336 . DOI: 10.1002/cncr.21622 http://doi.org/10.1002/cncr.21622 https://onlinelibrary.wiley.com/doi/10.1002/cncr.21622 https://onlinelibrary.wiley.com/doi/10.1002/cncr.21622

ELTING L S , COOKSLEY C D , CHAMBERS M S , et al . Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies [J ] . Int J Radiat Oncol Biol Phys , 2007 , 68 ( 4 ): 1110 - 1120 . DOI: 10.1016/j.ijrobp.2007.01.053 http://doi.org/10.1016/j.ijrobp.2007.01.053 https://linkinghub.elsevier.com/retrieve/pii/S0360301607002477 https://linkinghub.elsevier.com/retrieve/pii/S0360301607002477

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会 , 中国临床肿瘤学会肿瘤支持与康复治疗专家委员会 . 抗肿瘤治疗引起急性口腔黏膜炎的诊断和防治专家共识 [J ] . 临床肿瘤学杂志 , 2021 , 26 ( 5 ): 449 - 459 .

Expert Committee of Antitumor Drug Safety Management of Chinese Society of Clinical Oncology , Expert Committee of Cancer Support and Rehabilitation Therapy of Chinese Society of Clinical Oncology . Expert consencus on diagnosis, prevention and treatment of acute oral mucositis induced by anti-tumor therapy [J ] . Chin Clin Oncol , 2021 , 26 ( 5 ): 449 - 459 .

PETERSON D E , BENSADOUN R J , ROILA F , et al . Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines [J ] . Ann Oncol , 2011 , 22 ( Suppl 6 ): vi78 - vi84 . DOI: 10.1093/annonc/mdr391 http://doi.org/10.1093/annonc/mdr391 https://linkinghub.elsevier.com/retrieve/pii/S0923753419388052 https://linkinghub.elsevier.com/retrieve/pii/S0923753419388052

吴桐 , 程斌 . 肿瘤放化疗性口腔黏膜炎的防与治 [J ] . 中华口腔医学杂志 , 2022 , 57 ( 4 ): 436 - 440 .

WU T , CHENG B . Prevention and control strategy of radiotherapy-/chemotherapy-induced oral mucositis [J ] . Chin J Stomatol , 2022 , 57 ( 4 ): 436 - 440 .

DUNCAN G G , EPSTEIN J B , TU D S , et al . Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis [J ] . Head Neck , 2005 , 27 ( 5 ): 421 - 428 . DOI: 10.1002/hed.20162 http://doi.org/10.1002/hed.20162 https://onlinelibrary.wiley.com/doi/10.1002/hed.20162 https://onlinelibrary.wiley.com/doi/10.1002/hed.20162

ELAD S , CHENG K K F , LALLA R V , et al . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [J ] . Cancer , 2020 , 126 ( 19 ): 4423 - 4431 . DOI: 10.1002/cncr.33100 http://doi.org/10.1002/cncr.33100 https://onlinelibrary.wiley.com/doi/10.1002/cncr.33100 https://onlinelibrary.wiley.com/doi/10.1002/cncr.33100

中华医学会放射肿瘤治疗学分会 . 放射性口腔黏膜炎防治策略专家共识(2019) [J ] . 中华放射肿瘤学杂志 , 2019 , 28 ( 9 ): 641 - 647 .

Radiation Oncology Branch of the Chinese Medical Association . Expert consensus on prevention and control strategy of radiotherapy-induced oral mucositis (2019) [J ] . Chin J Radiat Oncol , 2019 , 28 ( 9 ): 641 - 647 .

BERNIER J , RUSSI E G , HOMEY B , et al . Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines [J ] . Ann Oncol , 2011 , 22 ( 10 ): 2191 - 2200 . DOI: 10.1093/annonc/mdr139 http://doi.org/10.1093/annonc/mdr139

FERRIS R L , BLUMENSCHEIN G Jr , FAYETTE J , et al . Nivolumab for recurrent squamous-cell carcinoma of the head and neck [J ] . N Engl J Med , 2016 , 375 ( 19 ): 1856 - 1867 . DOI: 10.1056/NEJMoa1602252 http://doi.org/10.1056/NEJMoa1602252 http://www.nejm.org/doi/10.1056/NEJMoa1602252 http://www.nejm.org/doi/10.1056/NEJMoa1602252

BURTNESS B , HARRINGTON K J , GREIL R , et al . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J ] . Lancet , 2019 , 394 ( 10212 ): 1915 - 1928 . DOI: S0140-6736(19)32591-7 http://doi.org/S0140-6736(19)32591-7

LEE N Y , FERRIS R L , PSYRRI A , et al . Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 4 ): 450 - 462 . DOI: 10.1016/S1470-2045(20)30737-3 http://doi.org/10.1016/S1470-2045(20)30737-3

MACHIELS J P , TAO Y , BURTNESS B , et al . LBA5 primary results of the phase Ⅲ KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) [J ] . Ann Oncol , 2022 , 33 : S1399 .

BOURHIS J , TAO Y , SUN X , et al . LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase Ⅲ GORTEC-REACH trial [J ] . Ann Oncol , 2021 , 32 : S1310 .

BONOMO P , DESIDERI I , LOI M , et al . Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: a phase Ⅰ/Ⅱ study (DUCRO) [J ] . Clin Transl Radiat Oncol , 2018 , 9 : 42 - 47 .

BONOMO P , DESIDERI I , MANGONI M , et al . Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial [J ] . Radiother Oncol , 2022 , 169 : 64 - 70 . DOI: 10.1016/j.radonc.2022.02.008 http://doi.org/10.1016/j.radonc.2022.02.008

FERRIS R L , MOSKOVITZ J , KUNNING S , et al . Phase Ⅰ trial of cetuximab, radiotherapy, and ipilimumab in locally advanced head and neck cancer [J ] . Clin Cancer Res , 2022 , 28 ( 7 ): 1335 - 1344 . DOI: 10.1158/1078-0432.CCR-21-0426 http://doi.org/10.1158/1078-0432.CCR-21-0426 https://aacrjournals.org/clincancerres/article/28/7/1335/682203/Phase-I-Trial-of-Cetuximab-Radiotherapy-and https://aacrjournals.org/clincancerres/article/28/7/1335/682203/Phase-I-Trial-of-Cetuximab-Radiotherapy-and

OVERGAARD J , HANSEN H S , OVERGAARD M , et al . A randomized double-blind phase Ⅲ study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85 [J ] . Radiother Oncol , 1998 , 46 ( 2 ): 135 - 146 . DOI: 10.1016/S0167-8140(97)00220-X http://doi.org/10.1016/S0167-8140(97)00220-X https://linkinghub.elsevier.com/retrieve/pii/S016781409700220X https://linkinghub.elsevier.com/retrieve/pii/S016781409700220X

SUN X S , TAO Y G , LE TOURNEAU C , et al . Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study [J ] . Lancet Oncol , 2020 , 21 ( 9 ): 1173 - 1187 . DOI: 10.1016/S1470-2045(20)30327-2 http://doi.org/10.1016/S1470-2045(20)30327-2 https://linkinghub.elsevier.com/retrieve/pii/S1470204520303272 https://linkinghub.elsevier.com/retrieve/pii/S1470204520303272

BOURHIS J , BURTNESS B , LICITRA L F , et al . Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase Ⅲ study design [J ] . Future Oncol , 2022 , 18 ( 14 ): 1669 - 1678 . DOI: 10.2217/fon-2021-1634 http://doi.org/10.2217/fon-2021-1634 https://www.futuremedicine.com/doi/10.2217/fon-2021-1634 https://www.futuremedicine.com/doi/10.2217/fon-2021-1634

浏览量

3777

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

局部晚期或转移性儿童及青少年分化型甲状腺癌的基因特征与临床特征及¹³¹I疗效的关系

个体化营养干预对局部晚期鼻咽癌患者生活质量及生存预后的影响